Education
About Us
Working with TipRanks
Follow Us
Biotage AB (SE:BIOT)
:BIOT
Top Page
Biotage AB
(OTC:BIOT)
72Outperform
Biotage AB (BIOT) vs. S&P 500 (SPY)
Market Cap
$11.32B
Dividend Yield1.62%
Average Volume (3M)888.44K
Price to Earnings (P/E)44.2
Beta (1Y)1.12
Revenue Growth-1.01%
EPS Growth6.10%
CountrySE
Employees622
SectorHealthcare
Sector Strength39
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.20
Shares Outstanding80,049,270
10 Day Avg. Volume770,052
30 Day Avg. Volume888,444
Financial Highlights & Ratios
PEG Ratio-4.35
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio59.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$143.02Price Target Upside1.08% Upside
Rating ConsensusHold
Number of Analyst Covering0
Biotage AB Business Overview & Revenue Model
Company DescriptionBiotage AB is a global life sciences company headquartered in Sweden, specializing in solutions in organic and analytical chemistry. The company provides instruments, consumables, and services designed to enhance the efficiency and productivity of scientists working in fields such as drug discovery, analytical chemistry, and environmental testing. Biotage's core product offerings include chromatography systems, sample preparation solutions, and synthesis tools, catering to a diverse range of industries including pharmaceuticals, biotechnology, and academia.
How the Company Makes MoneyBiotage AB generates revenue primarily through the sale of its scientific instruments and consumables. The company offers a comprehensive range of products that are integral to laboratory workflows, including systems for separation and purification, as well as sample preparation products. These products are sold directly to laboratories and research institutions worldwide. In addition to product sales, Biotage generates income through service contracts and support agreements, which provide ongoing maintenance and technical assistance to its customers. The company also benefits from strategic partnerships and collaborations with other firms in the life sciences sector, which can lead to joint development projects and expanded market reach.
Biotage AB Financial Statement Overview
Summary
Biotage AB presents a strong financial profile with robust revenue growth, profitability, and balance sheet stability. The company effectively manages its debt, maintaining low leverage while generating consistent earnings and cash flow. Despite some fluctuations in growth rates and margins, Biotage AB remains well-positioned within the Medical - Instruments & Supplies industry.Income Statement
Biotage AB has demonstrated strong financial performance with consistent growth in revenues and net income over the years. The company maintains a healthy gross profit margin of 62.7% for TTM, indicating efficient cost management. However, the net profit margin for TTM has slightly decreased to 13.1% from the previous annual figure of 13.8%. The revenue growth rate shows a slight decline of 4.6% from 2024 to TTM, but overall, the company's income statement reflects robust profitability and growth.82
Very Positive
Balance Sheet
The balance sheet of Biotage AB is solid with a strong equity base, reflected in an equity ratio of 81.7% for TTM. The company has effectively managed its debt levels, with a low debt-to-equity ratio of 0.06. Return on equity stands at 6.7% for TTM, indicating moderate efficiency in generating returns for shareholders. Overall, the balance sheet showcases financial stability with low leverage and high shareholder equity.88
Very Positive
Cash Flow
Biotage AB's cash flow statement indicates healthy cash generation capabilities, with a free cash flow of 188 million for TTM. However, the free cash flow has decreased by 22.9% compared to the previous year. The operating cash flow to net income ratio of 1.36 for TTM suggests efficient cash conversion from net income. Despite a decline in free cash flow, the company maintains a strong operating cash flow, reflecting good liquidity and cash management.75
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.96B | 2.06B | 1.86B | 1.57B | 1.23B | 1.09B | Gross Profit |
| 1.23B | 1.29B | 1.01B | 948.00M | 755.00M | 666.73M | EBIT |
| 312.00M | 383.00M | 376.00M | 327.00M | 271.00M | 206.19M | EBITDA |
| 491.00M | 568.00M | 432.00M | 431.00M | 323.00M | 278.10M | Net Income Common Stockholders |
| 256.00M | 284.00M | 246.00M | 268.00M | 205.00M | 175.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 420.00M | 434.00M | 594.00M | 441.00M | 311.00M | 371.32M | Total Assets |
| 4.71B | 5.10B | 4.93B | 2.34B | 1.99B | 1.43B | Total Debt |
| 238.00M | 250.00M | 259.00M | 217.00M | 203.00M | 212.69M | Net Debt |
| -182.00M | -184.00M | -335.00M | -224.00M | -108.00M | -158.63M | Total Liabilities |
| 862.00M | 991.00M | 1.27B | 702.00M | 620.00M | 444.40M | Stockholders Equity |
| 3.85B | 4.11B | 3.66B | 1.64B | 1.37B | 990.04M |
| Cash Flow | Free Cash Flow | ||||
| 188.00M | 244.00M | 258.00M | 271.00M | 297.00M | 218.11M | Operating Cash Flow |
| 348.00M | 413.00M | 284.00M | 341.00M | 353.00M | 279.05M | Investing Cash Flow |
| -437.00M | -456.00M | 35.00M | -84.00M | -341.00M | -61.32M | Financing Cash Flow |
| -158.00M | -156.00M | -142.00M | -133.00M | -82.00M | -22.72M |
Biotage AB Technical Analysis
Positive
141.50
Price Trends
110.95
Positive
125.13
Positive
149.30
Negative
Market Momentum
10.00
Positive
78.18
Negative
44.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOT, the sentiment is Positive. The current price of 141.5 is above the 20-day moving average (MA) of 130.60, above the 50-day MA of 110.95, and below the 200-day MA of 149.30, indicating a neutral trend. The MACD of 10.00 indicates Positive momentum. The RSI at 78.18 is Negative, neither overbought nor oversold. The STOCH value of 44.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOT.
Biotage AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $11.32B | 44.21 | 6.41% | 1.62% | -1.01% | 6.10% | |
71 Outperform | $10.66B | 47.68 | 25.53% | 0.21% | 20.72% | 122.06% | |
69 Neutral | $23.22B | 75.09 | 5.83% | 0.24% | 6.33% | 291.12% | |
68 Neutral | $19.43B | 151.45 | 18.01% | ― | 52.17% | -54.60% | |
67 Neutral | $10.22B | 76.57 | 6.57% | ― | 32.98% | 35.77% | |
52 Neutral | $5.14B | 3.39 | -43.55% | 2.83% | 16.49% | -0.19% |
* Healthcare Sector Average
Performance Comparison
SE:BIOT
Biotage AB
141.30
-35.12
-19.91%
SE:ALIF.B
AddLife AB
186.80
73.55
64.95%
SE:RAY.B
RaySearch Laboratories AB
314.50
192.79
158.40%
SE:BONEX
BONESUPPORT HOLDING AB
279.80
34.80
14.20%
SE:XVIVO
Xvivo Perfusion AB
333.00
-60.50
-15.37%
Biotage AB Earnings Call Summary
Earnings Call Date:Apr 23, 2025
(Q1-2024)
| % Change Since: 1.54%|
Next Earnings Date:Jul 16, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth and performance in the Astrea business and recurring revenues, yet faced challenges in meeting demand in the peptide segment and significant downturns in the China market and small molecules segment.Q1-2024 Updates
Positive Updates
Strong Revenue Growth
The company reported a top line of SEK 480 million, representing a 33% growth over last year, with a gross margin increase to 63.1%.
Astrea Business Performance
Astrea business grew by 78% compared to Q1 2023, contributing significantly to the biologics and advanced therapeutics segment, which now accounts for 30% of total revenue.
High Recurring Revenue
Recurring revenue increased to 72% of total sales, up from 67% in the previous year.
Cash Conversion and EBITDA
The company converted SEK 171 million in cash and reported an adjusted EBITDA of SEK 126 million, up 28% from the previous year.
Negative Updates
Peptide Business Capacity Issues
The company was unable to meet the high demand in the peptide business, resulting in a missed opportunity for single-digit growth in the core business.
China Market Challenges
The company faced significant headwinds in China, contributing to a 17% negative growth in the APAC region.
Decline in Small Molecules and Diagnostics
The Small Molecules business saw declines, particularly impacted by suppressed activity in APAC, and the Diagnostics business experienced a 43% decrease year-over-year.
Company Guidance
During the Q1 2024 earnings call for Biotage (BIOT.ST), key financial metrics were highlighted, showcasing a strong quarter with SEK 480 million in revenue, marking a 33% growth over the previous year. The gross margin improved to 63.1%, up by 2.2 percentage points, and the company achieved an adjusted EBITDA of SEK 126 million, reflecting a 28% increase. Recurring revenue reached 72% of total revenue, with SEK 346 million, significantly rising from 67% the previous year, largely driven by Astrea, which experienced a remarkable 78% growth. Despite challenges in fulfilling peptide business demand, which led to a missed opportunity for additional growth, the company remains optimistic about future capacity expansions. Additionally, Biologics & Advanced Therapeutics now contribute to 30% of total revenue, with a notable 78% revenue increase from Astrea. The company also reported an adjusted cash flow from operations of SEK 171 million and concluded the quarter with SEK 683 million in gross cash and SEK 426 million in net cash. Looking ahead, Biotage anticipates ongoing growth and plans to enhance manufacturing capacity to meet rising demands in the peptide sector.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.